Tag Archives: The Stem Cell Blog

BeyondSpring (BYSI) vs. Editas Medicine (EDIT) Head to Head Comparison – The Lincolnian Online

BeyondSpring (BYSI) vs. Editas Medicine (EDIT) Head to Head ComparisonThe Lincolnian OnlineIt is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonuc… Continue reading

Reviewing BeyondSpring (NASDAQ:BYSI) and Editas Medicine (EDIT) – Week Herald

Reviewing BeyondSpring (NASDAQ:BYSI) and Editas Medicine (EDIT)Week HeraldIt is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) c… Continue reading

Stem cell transplant cures first adult sickle-cell patient in Canada – Calgary Herald

Calgary Herald

Stem cell transplant cures first adult sickle-cell patient in Canada Calgary Herald Agyepong was born with sickle-cell anemia, a hereditary disease in which blood cells change into a ‘sickle’ shape and block blood vessels causing severe pain and a risk of stroke leaving every organ at risk. She even made a bucket list at a very young … and more »

CNBC

Ex-Kite Execs Resurface with $300M and Control of Pfizer CAR–T Cells Xconomy Arie Belldegrun and David Chang steered Kite Pharma last year to a historic FDA approval and a $12 billion bear hug from Gilead Sciences. Now they’ve re-emerged with a new startup, Allogene, which has $300 million in backing and the rights to a CAR–T … Pfizer signs a deal with Allogene to develop a cancer cell therapyCNBC Pfizer in deal with Allogene to develop cancer cell therapies – ReutersReuters Pfizer inks deal handing CAR–T assets to newly launched biotechBioPharma Dive BioPharm International –BioPharma-Reporter.com –StreetInsider.com all 8 news articles »

Wall Street Morning

Time Out: Talking Strategy For CRISPR’s Big 3 Seeking Alpha By Christopher Lew, Senior Analyst DeciBio Consulting. Intellia (NTLA), Editas (EDIT), and CRISPR Therapeutics (CRSP) grew rapidly in the last year, reaching market caps of ~$900M, ~$1.5B, and ~$2.1B, respectively, and all holding cash positions of … Financially Devastating or Fantastic? – Frontier Communications Corporation (FTR), CRISPR Therapeutics AG (CRSP)StockNewsGazette Analysts recommended an average rating score of 2.10 for CRISPR Therapeutics AG (CRSP)Wall Street Morning CRISPR Therapeutics (CRSP) Stock Price Down 1.3%Macon Daily Stocks Market Cap –The Stocks News (press release) –The Lincolnian Online all 13 news articles »

Gene-Editing Start-Up Poseida Lands $30.5M to Advance CAR T hcanews.com Read: Fighting Cancer with CAR T and Big Data The first CAR T therapies gained FDA approval last year. Kymriah, a fruit of Novartis’s efforts, first got the green light in August, followed by Kite Pharma’s Yescarta. CAR T, of course, involves the …